Companies
Sansure Biotech
a STAR Market-listed Chinese in-vitro diagnostics company that scaled domestic point-of-care molecular testing manufacturing and distribution capacity, continuing as a leading domestic IVD platform provider.
- Country
- China
Commercial
Domestic POCT molecular platforms
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $77 million total funding (2018-01-02) | vcbeathealth.com |
| Revenue | 1.458 billion yuan (2024-12-31) | news.futunn.com · blackroseband.com · mlznjz.com · moomoo.com |
| Headcount | 581 R&D personnel (2024-12-31) | moomoo.com |
| Production site | Changsha industrial base and Shanghai industrial base (2024-12-31) | sansureglobal.com |
| Certification | ISO 13485, ISO 9001, ISO 15189, and CE-IVDR/CE-marked certifications | sansureglobal.com · sse.com.cn |
| Regulatory approval | Over 1,800 domestic and international registrations and approvals, including NMPA (China) and US FDA EUA | sansureglobal.com · lavfund.com · sse.com.cn · vcbeathealth.com |
Independent sources: blackroseband.com · lavfund.com · mlznjz.com · moomoo.com · news.futunn.com · sansureglobal.com · sse.com.cn · vcbeathealth.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Point-of-care molecular diagnostics | diagnostics-medtech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.